Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.37 |
| ▸ | TK2 | O00142 | 2/20 | 0.35 |
| ▸ | TK1 | P04183 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PYGB | P11216 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973110 | 0.85 | PYGM (0.37) | PYGMTK2TK1LMNASMN1; SMN2 | |
| SCHEMBL3978670 | 0.85 | PYGM (0.37) | PYGMTK2TK1LMNASMN1; SMN2 | |
| SCHEMBL3968348 | 0.82 | PYGM (0.35) | PYGMTK2TK1LMNASMN1; SMN2 | |
| SCHEMBL27349255 | 0.82 | TK1 (0.42) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL3079827 | 0.81 | PYGM (0.34) | PYGMTK2TK1LMNASMN1; SMN2 | |
| SCHEMBL3977864 | 0.78 | RNASE1 (0.35) | PYGMTK2 | |
| SCHEMBL31398394 | 0.78 | TK2 (0.56) | TK2TK1CYP1A2CYP3A4TSHR | |
| SCHEMBL3087451 | 0.76 | LMNA (0.37) | PYGMTK2TK1LMNASMN1; SMN2 | |
| SCHEMBL154357 | 0.74 | SLC28A1 (0.49) | — | |
| SCHEMBL7257326 | 0.74 | PYGM (0.39) | PYGMTK2TK1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054406-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotect GmbH (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008017515-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |